- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07639684
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D) (MEASURE)
Metabolic Effects of Endoscopic Sleeve Gastroplasty in Obese Adults With Type 2 Diabetes: Evaluation of Glycemic Control, Insulin Use and Obesity Response
The goal of this clinical trial is to determine whether Endoscopic Sleeve Gastroplasty (ESG)-induced weight loss can improve glycemic outcomes and alter the trajectory toward insulin dependence in adults with obesity and inadequately controlled Type 2 Diabetes (T2D) despite guideline-directed therapy, including Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA)-based agents.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Bridget Stanford
- Telefonnummer: 781-305-0506
- E-Mail: bridget.stanford@bsci.com
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Willing and able to provide written informed consent to participate in the study
- Age ≥ 22 years
- BMI 30 - 50 kg/m2
- HbA1c 7.5 - 10.5%
- Type 2 Diabetes treated with incretin-based medication (aka GLP-1RA agonist or GLP-1RA/GIP dual agonist) at a stable, maximal tolerated dose for a minimum of 6 months +/- any other oral glucose lowering medications AND intention to initiate insulin therapy for glycemic management
- Stable weight (< 5% TBW) within the 3 months prior to screening
- Meets the indications for ESG procedure with OverStitch™ or OverStitch NXT™ Endoscopic Suturing System, excluding the following but not limited to the following: large hiatal hernia, potential bleeding gastric lesions (e.g. ulcers; erosive gastritis; varices; or vascular malformation), coagulopathy and antiplatelet/anticoagulant therapy that cannot be corrected
- Declines or is ineligible for metabolic bariatric surgery
- Agrees to abstain from taking any weight loss treatments or supplements that are not part of the lifestyle modification program for a year following the ESG procedure
- Willing and able to comply with the study procedure with standard of care lifestyle modification program and visit schedule.
Exclusion Criteria:
- Diabetes management with insulin. Prior use of insulin for gestational diabetes or short-term use (up to 1 month) in conjunction with an acute condition is acceptable.
- Noncompliance with medication regime for diabetic management
- More than one episode of clinically significant reactive or severe hypoglycemia within the prior 1 year. Reactive hypoglycemia is defined as postprandial hypoglycemia meeting Whipple's Triad; severe hypoglycemia is defined as any hypoglycemic episode requiring assistance from another person to administer carbohydrates, glucagon, or other corrective/resuscitative action
- History of ketoacidosis or hyperosmolar nonketotic coma within the past 1 year
- Has a contraindication for ESG procedure with OverStitch™ or OverStitch NXT™ Endoscopic Suturing System, including but not limited to the following: large hiatal hernia, potential bleeding gastric lesions (e.g. ulcers; erosive gastritis, varices, or vascular malformation), coagulopathy and antiplatelet/anticoagulant therapy that cannot be correct
- Prior gastric surgery, including but not limited to LSG or RYGP
- Any known conditions that impact weight loss or glycemic management
- Chronic systemic steroids or immunosuppressants taken at the time of enrollment or likely required during the study follow-up
- CKD stage 3+, defined as eGFR < 60 mL/min
- Persistent anemia, defined as hemoglobin < 10 g/dL
- Excessive alcohol consumption, defined as meeting or exceeding sex-based heavy drinking limits
- Use within the last three months prior to screening of over the counter or prescribed weight loss supplements / medications, or intent to use any weight loss medications or supplements during the study duration.
- The investigator's medical judgment that the subject is not a candidate for the ESG procedure due to findings, including but not limited to psychological and nutritional evaluation results obtained in the prior 12 months.
- Current pregnancy confirmed by site standard of care or planned pregnancy or breastfeeding for a year following the ESG procedure.
- Vulnerable subject.
- Current or planned participation in another clinical study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Endoscopic Sleeve Gastroplasty (ESG) Procedure
|
Endoscopic Sleeve Gastroplasty (ESG) with OverStitch Endoscopic Suturing System. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Serious Adverse Events
Zeitfenster: Through study completion, 12 months post procedure
|
Serious Adverse Events related to the study procedure and/or study device defined as Grade III or greater according to Clavien-Dindo Classification |
Through study completion, 12 months post procedure
|
|
Average Change in HbA1c
Zeitfenster: 12 months post procedure
|
Mean change in HbA1c from baseline to 1-year. If rescue treatment is initiated, the last HbA1c value before initiation of rescue treatment is used for assessment of the primary effectiveness endpoint. |
12 months post procedure
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of Subjects Achieving HbA1c < 7%
Zeitfenster: 12 months post procedure
|
Proportion of subjects achieving HbA1c < 7% without initiating rescue treatment at 1-year |
12 months post procedure
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Weight Loss
Zeitfenster: 1, 3, 6, 9, and 12 months post procedure
|
Total Body Weight Loss (TBWL) % and Excess Weight Loss (EWL) % at each visit |
1, 3, 6, 9, and 12 months post procedure
|
|
Proportion of Subjects with a Total Body Weight Loss ≥ 10%
Zeitfenster: 1, 3, 6, 9, and 12 months post procedure
|
Proportion of subjects with a TBWL ≥ 10% at each visit |
1, 3, 6, 9, and 12 months post procedure
|
|
Proportion of Subjects Achieving HbA1c < 6.5%
Zeitfenster: 12 months post procedure
|
Proportion of subjects achieving HbA1c < 6.5% without initiating rescue treatment at 1-year |
12 months post procedure
|
|
Proportion of Subjects Achieving TBWL ≥ 10% AND HbA1c < 6.5%
Zeitfenster: 12 months post procedure
|
Proportion of subjects with a TBWL ≥ 10% AND a HbA1c < 6.5% without initiating rescue treatment at 1-year |
12 months post procedure
|
|
Proportion of Subjects Initiating Rescue Treatment
Zeitfenster: Through study completion, 12 months post procedure
|
Proportion of subjects initiating rescue treatment at any time during the study follow-up period |
Through study completion, 12 months post procedure
|
|
Proportion of Subjects Meeting Rescue Criteria
Zeitfenster: Through study completion, 12 months post procedure
|
Proportion of subjects meeting rescue criteria at any time during the study follow-up period |
Through study completion, 12 months post procedure
|
|
Proportion of Subjects with Improvement in Comorbidities
Zeitfenster: 12 months post procedure
|
Proportion of subjects with improvement in each specific obesity-related comorbidity, as applicable, from baseline to 1-year: Hypertension, Dyslipidemia, Obstructive sleep apnea, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) |
12 months post procedure
|
|
Change in Vitals
Zeitfenster: 6 and 12 months post procedure
|
Change in vitals from baseline to 6-months and from baseline to 1-year: Systolic blood pressure, Diastolic blood pressure |
6 and 12 months post procedure
|
|
Change in Blood Laboratory Tests
Zeitfenster: 6 and 12 months post procedure
|
Change in blood laboratory tests from baseline to 6-months and from baseline to 1-year: fasting plasma glucose, estimated glomerular filtration rate (eGFR), aspartate aminotransferase (AST), alanine aminotransferase (ALT,) low-density lipoprotein cholesterol (LDL-C), Triglycerides |
6 and 12 months post procedure
|
|
Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Zeitfenster: 6 and 12 months post procedure
|
Change in HOMA-IR from baseline to 6-months and from baseline to 1-year |
6 and 12 months post procedure
|
|
Change in Fibrosis-4 (FIB-4)
Zeitfenster: 6 and 12 months post procedure
|
Change in FIB-4 from baseline to 6-months and from baseline to 1-year |
6 and 12 months post procedure
|
|
Change in Nonalcoholic Fatty Liver Disease (NAFLD) Fibrosis Score
Zeitfenster: 6 and 12 months post procedure
|
Change in NAFLD Fibrosis Score (NFS) from baseline to 6-months and from baseline to 1-year |
6 and 12 months post procedure
|
|
Change in Diabetes Treatment Satisfaction
Zeitfenster: 12 months post procedure
|
Change in diabetes treatment satisfaction, as assessed by Diabetes Treatment Satisfaction Questionnaire - status (DTSQs), from baseline to 1-year and Diabetes Treatment Satisfaction Questionnaire - change (DTSQc) at 1-year; Positive score indicates an improvement in satisfaction, or a reduction in the frequency of hyper/hypoglycemia. Negative score indicates a deterioration in satisfaction, or an increase in the frequency of hyper/hypoglycemia. Zero indicates no change in satisfaction or symptoms. |
12 months post procedure
|
|
Change in Diabetes Self-Care Activity
Zeitfenster: 6 and 12 months post procedure
|
Change in diabetes self-care activity, as assessed by Summary of Diabetes Self-Care Activity (SDSCA), from baseline to 6-months and from baseline to 1-year; Higher scores indicate better compliance with diabetic self-care recommendations. Lower scores point to areas where the patient may be struggling or may need additional education and support. |
6 and 12 months post procedure
|
|
Change in Quality of Life
Zeitfenster: 12 months post procedure
|
Change in quality of life, as assessed by 36-Item Short Form Health Survey (SF-36) domain scores and Physical and Mental Component Summaries (PCS and MCS), from baseline to 1-year; Higher scores indicate a better, higher quality of life and fewer health-related limitations. |
12 months post procedure
|
|
Adverse Events
Zeitfenster: Through study completion, 12 months post procedure
|
Adverse events associated with study procedure and/or study device |
Through study completion, 12 months post procedure
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Shailendra Singh, MD, West Virginia University
- Hauptermittler: Ildiko Lingvay, MD, UT Southwestern
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des endokrinen Systems
- Ernährungsstörungen
- Stoffwechselerkrankungen
- Überernährung
- Körpergewicht
- Störungen des Glukosestoffwechsels
- Diabetes Mellitus
- Übergewicht
- Pathologische Zustände, Anzeichen und Symptome
- Ernährungs- und Stoffwechselerkrankungen
- Anzeichen und Symptome
- Fettleibigkeit
- Diabetes mellitus, Typ 2
Andere Studien-ID-Nummern
- E7233
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .